Nearly millions of people throughout the world are living with chronic pain in one form or the other. With the rise of opioids in the epidemic level, there arises a rise in search for new treatment measures.

The wearables company named NeuroMetrix had redesigned their device named Quell for an easier and convenient utilization. The modified Quell 2.0 app has taken the FDA approved nerve stimulation technology to the next level, which is supposed to be the latest breakthrough for chronic pain treatment. The Quell 2.0 device is smarter, 50% smaller and 20% more powerful. The new Quell 2.0 app is available online at www.QuellRelief.com.

Quell 2.0 app is integrated with a neurostimulation microchip which includes all the features of Quell device. It easily adapts to changes in body position and automatically starts the therapy in switch-on mode. This app is user-friendly with a varied automation feature like start and stop, and track therapy, activity, sleep and pain. Quell 2.0 app can be worn on the upper calf to activate the pain relief response. This app can be used during daytime while active and during night time while sleeping.

Shai N. Gozani, M.D., Ph.D., the President and CEO of NeuroMetrix, said "Since first launching Quell in 2015, over 100,000 individuals living with chronic pain have experienced Quell's patented neurotechnology. Feedback from our customers and new research has enabled us to create a more intelligent, powerful and compact device. We believe that technology can have a positive impact on chronic pain and look forward to helping even more consumers find relief with Quell 2.0."